Marina A. Parry

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Characteristics and outcomes of men presenting with complications of metastatic prostate cancer.

Characteristics and outcomes of men presenting with complications of metastatic prostate cancer.

Journal: BJU international

Published: February 18, 2026

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Journal: Blood advances

Published: December 09, 2025

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Journal: Blood advances

Published: December 09, 2025

Future Directions of the National Prostate Cancer Audit.

Future Directions of the National Prostate Cancer Audit.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: November 26, 2025

Comparing the national cancer waiting times dataset with other linked electronic health records to measure treatment timeliness: A national cohort study of kidney cancer in England.

Comparing the national cancer waiting times dataset with other linked electronic health records to measure treatment timeliness: A national cohort study of kidney cancer in England.

Journal: Cancer epidemiology

Published: September 18, 2025

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Journal: Cell

Published: January 23, 2025

Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England.

Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 13, 2025

Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation.

Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation.

Journal: BMJ oncology

Published: October 17, 2024

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

Journal: The Lancet. Digital health

Published: January 10, 2024

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Journal: Research square

Published: February 17, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026